Mosialos: How effective are vaccines against Omicron – The “cocktail” with the greatest protection

The new data on the effectiveness of vaccines against Omicron mutation in terms of serious disease and cellular immunity were reported by the professor of Health Policy of the London School of Economics (LSE), Elias Mosialos, in a post on Facebook.

He stressed that the protection of vaccines against hospitalization after Omicron infection is much greater than that against symptomatic disease, while from the third dose the effectiveness of the vaccine against hospitalization is very high.

In detail, his post:

“Newer for micronutrients: post-vaccination protection, disease severity and cellular immunity

New data from the United Kingdom on the protection of vaccines against the Omicron variant have been published. The data come from an analysis of tests conducted between November 27 and December 24 and included 169,888 certified delta cases and 204,036 micron cases. (https: //assets.publishing.service.gov.uk /…/ Technical …).

In more detail, and regarding the possibility of someone being vaccinated having symptoms if they catch the micron:

Among those who have taken two doses of AstraZeneca, the efficacy of the symptom vaccine is almost 40% 10 weeks after the 3rd booster dose of the Pfizer vaccine, and almost 60% 5-9 weeks after the 3rd booster dose with the Moderna vaccine.

2. Among those who took two doses of Pfizer, the efficacy against symptomatic disease decreased to almost 50% 10 weeks after the 3rd booster dose of the Pfizer vaccine and to almost 70% 5-9 weeks after the 3rd booster dose with Moderna vaccine.

There is not yet enough data to calculate the efficacy of the vaccine against hospitalization by vaccine type, but this is expected to be done soon.

But, from the data at present:

1. The risk of hospitalization after omicron infection is 60-70% lower than delta infection (with the available data for the analysis of the severity of the disease).

2. Regardless of whether someone is infected with either the delta variant or the micron, a 3rd dose significantly reduces the chance of hospitalization (by 85-90% compared to the non-vaccinated).

Of course, further data are needed to investigate the duration of protection against serious micronutrient disease provided to us by vaccines. However, studies (cellular memory) of the previous variants suggest that this will be greater than protection against symptomatic disease.

Also, a new study from America whose results were based on the analysis of 862 micron samples, 3159 alpha samples and 15639 delta samples (https://doi.org/10.1101/2021.12.30.21268560) obtained from symptomatic patients, which confirmed superior in transmissibility or micron over any other variant, also showed that:

1. The micron caused significantly more cases of infection after vaccination than alpha or delta.

2. Significantly fewer patients with micronized disease required hospitalization compared to patients with alpha or delta disease.

3. The median length of stay for patients treated with omicron was significantly shorter than for patients with alpha or delta. In addition, the maximum respiratory support required for patients treated with micron was significantly lower than for patients with alpha or delta.

Let me remind you that all these data do not necessarily mean that the micron does not cause serious disease in the unvaccinated. But the risk is much lower than the delta for the vaccinated.

So we have good news. The protection of vaccines against hospitalization after omicron infection is much greater than that against symptomatic disease.

After the third dose the effectiveness of the vaccine against hospitalization is very high. However, the unvaccinated should be rushed to be vaccinated and the vaccinated with 2 doses should make the third dose “.

Follow Skai.gr on Google News
and be the first to know all the news